Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction.
暂无分享,去创建一个
Sameer Ather | Anita Deswal | Wenyaw Chan | Biykem Bozkurt | David Aguilar | W. Chan | B. Bozkurt | X. Wehrens | Xander H.T. Wehrens | K. Ramasubbu | A. Deswal | Sameer Ather | D. Aguilar | Kumudha Ramasubbu | Amit A. Zachariah | A. Zachariah
[1] D. Levy,et al. A Systematic Assessment of Causes of Death After Heart Failure Onset in the Community: Impact of Age at Death, Time Period, and Left Ventricular Systolic Dysfunction , 2011, Circulation. Heart failure.
[2] H. Krumholz,et al. Outcomes in heart failure patients with preserved ejection fraction: mortality, readmission, and functional decline. , 2003, Journal of the American College of Cardiology.
[3] M. Senni,et al. Heart failure with preserved systolic function. A different natural history? , 2001, Journal of the American College of Cardiology.
[4] T. Therneau,et al. Hospitalizations after heart failure diagnosis a community perspective. , 2009, Journal of the American College of Cardiology.
[5] N. Freemantle,et al. Perindopril for elderly people with chronic heart failure: the PEP‐CHF study , 1999, European heart journal.
[6] V. Roger,et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. , 2006, The New England journal of medicine.
[7] M. Rich,et al. Age disparities in heart failure research. , 2010, JAMA.
[8] Chad Boult,et al. Comprehensive primary care for older patients with multiple chronic conditions: "Nobody rushes you through". , 2010, JAMA.
[9] Li-sheng Liu,et al. Treatment of hypertension in patients 80 years of age or older. , 2008, The New England journal of medicine.
[10] J. McMurray,et al. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology , 2009, European journal of heart failure.
[11] Karl Swedberg,et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial , 2003, The Lancet.
[12] Susan Anderson,et al. Irbesartan in patients with heart failure and preserved ejection fraction. , 2008, The New England journal of medicine.
[13] Harlan M Krumholz,et al. The association of left ventricular ejection fraction, mortality, and cause of death in stable outpatients with heart failure. , 2003, Journal of the American College of Cardiology.
[14] Z. Massy,et al. Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study. , 2008, European heart journal.
[15] B. Bozkurt,et al. Obesity as a prognostic factor in chronic symptomatic heart failure. , 2005, American heart journal.
[16] R. Beyth,et al. Racial variations in quality of care and outcomes in an ambulatory heart failure cohort. , 2006, American heart journal.
[17] D. Levy,et al. A Systematic Assessment of Causes of Death After Heart Failure Onset in the CommunityClinical Perspective , 2011 .
[18] D. Horstkotte,et al. Adaptive servoventilation in diastolic heart failure and Cheyne–Stokes respiration , 2010, European Respiratory Journal.
[19] D. Mancini,et al. The effect of erythropoietin on exercise capacity, left ventricular remodeling, pressure-volume relationships, and quality of life in older patients with anemia and heart failure with preserved ejection fraction. , 2009, Congestive heart failure.
[20] C. Mackenzie,et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.
[21] Tom Greene,et al. Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate , 2006, Annals of Internal Medicine.
[22] M. Cheitlin,et al. Outcome of Heart Failure with Preserved Ejection Fraction in a Population-Based Study , 2008 .
[23] Albert W Wu,et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. , 2003, Journal of the American College of Cardiology.
[24] Nancy M Albert,et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. , 2007, Journal of the American College of Cardiology.
[25] K. Swedberg,et al. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. , 2004, Journal of the American College of Cardiology.
[26] J. McMurray,et al. Heart failure with preserved left ventricular systolic function: a hospital cohort study , 2005, Heart.
[27] Paul W Armstrong,et al. Anemia Is Common in Heart Failure and Is Associated With Poor Outcomes: Insights From a Cohort of 12 065 Patients With New-Onset Heart Failure , 2003, Circulation.
[28] B. Davis,et al. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.
[29] C. Yancy,et al. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. , 2006, Journal of the American College of Cardiology.
[30] V. Roger,et al. Death in Heart Failure: A Community Perspective , 2008, Circulation. Heart failure.